Post-Conference Perspectives: Updates on TIL Therapy for Solid Tumors, Including Melanoma and NSCLC

home / news-network / post-conference-perspectives-updates-on-til-therapy-for-solid-tumors

Expert perspectives from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the evolving role of tumor-infiltrating lymphocyte therapy in solid tumors, following the Society for Immunotherapy of Cancer (SITC) 2022 meeting.

© 2024 MJH Life Sciences

All rights reserved.